Skip to Main Content

Insight

June 18, 2026
Cannabis and Psychedelics Monthly Newsletter

the buzz: Cannabis News & Policy Update | June 2026

Welcome back to the buzz, our monthly cannabis news and policy update. Your at-a-glance source for regulatory developments, agency announcements, and trends impacting the cannabis industry.

In this edition of the buzz, highlights include:

  • Rescheduling under fire: Three legal challenges trying to overturn the move of medical marijuana products to Schedule III now consolidated in the DC Circuit. Challengers also trying to freeze order and halt DEA’s administrative hearings.  
  • SCOTUS & gun rights: Supreme Court unanimously rules that marijuana use alone cannot automatically bar firearm ownership under the Second Amendment.
  • 280E clarity elusive: Two congressional letters push Treasury and IRS for guidance on how rescheduling affects deductions, but nothing yet on transition rules to help operators navigate; DOJ tries to claw back $8.3M tax refund from TerrAscend in 280E fight.
  • New markets open: AL's first medical dispensary is operational, IA doubles its dispensary cap, and VA explores moving adult-use sales through the state budget after a gubernatorial veto.
  • State policy shifts: CT swaps its potency tax for a flat excise; IL sends an omnibus bill to the governor; MI's new wholesale tax is underperforming projections; MN merges its medical and adult-use supply chains.
  • Hemp rules tightening: TX court lets new smokable hemp restrictions and steep fee increases take effect; OH proposes rescinding cultivation rules; TN transitions hemp oversight to its alcoholic beverage commission July 1.

Read Here

Want the buzz delivered monthly?
Never miss a cannabis news and policy update. Use the button below to sign up for future monthly newsletters.

Sign Up


Subscribe to get our Insights delivered to your inbox.

This publication is designed to provide general information on pertinent legal topics. The statements made are provided for educational purposes only. They do not constitute legal or financial advice nor do they necessarily reflect the views of Holland & Hart LLP or any of its attorneys other than the author(s). This publication is not intended to create an attorney-client relationship between you and Holland & Hart LLP. Substantive changes in the law subsequent to the date of this publication might affect the analysis or commentary. Similarly, the analysis may differ depending on the jurisdiction or circumstances. If you have specific questions as to the application of the law to your activities, you should seek the advice of your legal counsel.

Holland & Hart Authors

Related Capabilities

Cannabis and Psychedelics
DISCLAIMER

Unless you are a current client of Holland & Hart LLP, please do not send any confidential information by email. If you are not a current client and send an email to an individual at Holland & Hart LLP, you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us, unless we have already agreed to represent you or we later agree to do so. Thus, we may represent a party adverse to you, even if the information you submit to us could be used against you in a matter, and even if you submitted it in a good faith effort to retain us.